HER2 ADCs in Gynecologic Cancers

CME

Emerging HER2-Targeted Antibody–Drug Conjugates in Gynecologic Cancers

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: May 09, 2024

Expiration: November 08, 2025

Kathleen N Moore
Kathleen N Moore, MD, MS

Activity

Progress
1 2
Course Completed

References

  1. Buza N. HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand. Arch Pathol Lab Med. 2020;145:687-691.
  2. Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu (NCT01367002): updated overall survival analysis. Clin Cancer Res. 2020;26:3928-3935.
  3. Itkin B, Garcia A, Straiminsky S, et al. Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis. PLoS One.2021;16:e0257976.
  4. Wolf AC, Hammond ME, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologist Clinical Practice Guidelines focused update. J Clin Oncol. 2018;36:2105-2122.
  5. Kamangar E, Bishop J. Current challenges for HER2 immunohistochemistry testing in diagnostic pathology. Cancer Care. health.ucdavis.edu/blog/lab-best-practice/current-challenges-for-her2-immunohistochemistry-testing-in-diagnostic-pathology/2019/05. Accessed April 29, 2024.
  6. Moore KN, Makker V, Yeku Oladapo, et al. DB-1303, a HER2-targeting ADC, for patients with recurrent/metastatic endometrial cancer: preliminary clinical results from an ongoing phase 1/2a trial. Presented at: 2023 European Society of Gynaecological Oncology Congress; September 28 - October 1, 2023. Abstract 430.
  7. Slamon DJ, Leyland-Jone B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
  8. Cuello M, Ettenberg SA, Clark AS, et al. Down-regulation of the ERBB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2021;61:4892-4900.
  9. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: uterine neoplasms. v.2.2024. nccn.org. Accessed April 29, 2024.
  10. Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:283-290.
  11. Fortman D, Issa R, Stanbery L, et al. HER2-positive metastatic cervical cancer responsive to first and second-line treatment: a case report. Gynecol Oncol Rep. 2019;31:100520.
  12. Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 2 trial (Gynecologic Oncology Group 240). Lancet. 2017;390:1654-1663.
  13. Pembrolizumab [prescribing information]. Rahway, NJ: Merck Sharp & Dohme; 2024.
  14. Nakada T, Sugihara K, Jikoh T, et al. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67:173-185.
  15. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. Presented at: 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract LBA3000.
  16. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42:47-58.
  17. Tisotumab vedotin [prescribing information]. Bothell, WA and Plainsboro, NJ: Seagen and Genmab US; 2023.  
  18. Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:609-619.
  19. Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III Study 309/KEYNOTE-775. J Clin Oncol. 2023;41:2904-2910.
  20. Moore K, Angelergues A, Konecny GE, et al. Mirvetuximab soravtansine in FRα-positive, platinum resistant, ovarian cancer. N Engl J Med. 2024;389:2162-2174.
  21. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385:1856-1867.
  22. Lin S, Shi R, Li B, et al. An exatecan derivative based linked-payload platform leads to ADC products with promising anti-tumor efficacy and potential low interstitial lung disease (ILD). Eur J Cancer. 2022;174:S91.
  23. Trastuzumab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2024.
  24. Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022;106:102378.